BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19671842)

  • 1. CIP2A is associated with human breast cancer aggressivity.
    Côme C; Laine A; Chanrion M; Edgren H; Mattila E; Liu X; Jonkers J; Ivaska J; Isola J; Darbon JM; Kallioniemi O; Thézenas S; Westermarck J
    Clin Cancer Res; 2009 Aug; 15(16):5092-100. PubMed ID: 19671842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
    Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of sCIP2A levels in breast cancer.
    Xing ML; Lu YF; Wang DF; Zou XY; Zhang SX; Yun Z
    Eur Rev Med Pharmacol Sci; 2016; 20(1):82-91. PubMed ID: 26813457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
    Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
    Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells.
    Li W; Ge Z; Liu C; Liu Z; Björkholm M; Jia J; Xu D
    Clin Cancer Res; 2008 Jun; 14(12):3722-8. PubMed ID: 18559589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
    Guo Z; Liu D; Su Z
    Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
    Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
    Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein.
    Liu J; Wang X; Zhou G; Wang H; Xiang L; Cheng Y; Liu W; Wang Y; Jia J; Zhao W
    Gynecol Oncol; 2011 Aug; 122(2):430-6. PubMed ID: 21575984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer.
    Chen W; Liang JL; Zhou K; Zeng QL; Ye JW; Huang MJ
    Cell Commun Signal; 2020 Apr; 18(1):67. PubMed ID: 32321509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
    Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
    J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
    Guo Z; Liu D; Su Z
    Tumour Biol; 2015 May; 36(5):3583-9. PubMed ID: 25560487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
    Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
    Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
    Zhao Q; Zhao M; Parris AB; Xing Y; Yang X
    Int J Oncol; 2016 Sep; 49(3):1203-10. PubMed ID: 27574003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in CIP2A expression is associated with doxorubicin resistance.
    Choi YA; Park JS; Park MY; Oh KS; Lee MS; Lim JS; Kim KI; Kim KY; Kwon J; Yoon DY; Moon EY; Yang Y
    FEBS Lett; 2011 Mar; 585(5):755-60. PubMed ID: 21241697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
    Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z
    Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
    Zhai M; Cong L; Han Y; Tu G
    Tumour Biol; 2014 Feb; 35(2):1123-8. PubMed ID: 24014087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
    Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
    Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.